Horizontal surface | Baiyunshan's pharmaceutical companies have been cash -up, and have been "pulled black" by many places before, which affects the geometry on performance?

New Yellow River Reporter: Liu Jinyang

WeChat public account of the State Medical Insurance Bureau on August 9th. Recently, the State Medical Insurance Bureau, in accordance with relevant departments, guides relevant provinces to guide relevant provinces to Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Three companies including the factory, Guangzhou Baiyunshan Jingxiu Pharmaceutical Co., Ltd., and other three companies' drug virtual high prices and set up funds for special investigations.

After investigation, the enterprises and agents involved in collusion, after the designated "dealer" was scheduled, the price raised several times to dozens of times to cash out. The amount involves huge amounts, and some of them are used for bribery medical staff or specific relationship persons to carry out drug violations.

Public information shows that the three companies involved are the holding subsidiaries under Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Baiyun Mountain"). Baiyunshan Pharmaceutical General Factory is Baiyunshan Branch. Tianxin Pharmaceutical and Jingxiu Hall are subsidiaries of Bai Yunshan direct control.

A reporter from Xinhuanghe found that before, Baiyunshan had been "pulling black" in many places to cancel the winning standard because "according to the requirements of the National Medical Insurance Bureau, drug discontinuation or duplicate products", etc. For reasons, they have repeatedly applied for exit exit qualifications. Pharmaceutical hanging nets, that is, pharmaceutical manufacturers and operating enterprises bid to the drug bidding office. Baiyunshan was canceled, which means that the opportunity to win the bid and cannot hang the Internet again in a certain period of time, and the company may be included in the list of poor reputation. The opportunity to participate in the collection and subsequent promotion will be greatly received in the future. influences.

On August 10, a reporter from Xinhuanghe tried to contact Bai Yunshan many times, and as of the press time, it was not responded. Earlier, Bai Yunshan announced that it had been notified of three companies that had been announced that it had instructed the company to stop cooperating with relevant agents and dealers, and the relevant responsible person was removed or suspended. People in the industry told the media that the National Medical Insurance Bureau publicly notified Bai Yunshan's violations, showing the attitude of combating the bad wind of the pharmaceutical industry. The National Medical Insurance Bureau stated that it will continue to guide the provinces in conjunction with relevant departments to continue to correct the inappropriate wind in the field of pharmaceutical purchase and sales.

Specify the intermediate merchant transfer cash

According to the National Medical Insurance Bureau survey, from 2017 to May 2021, three pharmaceutical manufacturers including Tianxin Pharmaceuticals in order to avoid the "two -vote system" policies and supervision, and they colluded with more than 50 pharmaceutical agents downstream. The 87 kinds of drugs were cash out by the way to purchase raw medicines in virtual high -priced prices, and transferred funds to downstream drug agents.

According to the company's investigation, Tianxin Pharmaceuticals held 82.49%of Baiyunshan, and Jingxiutang Pharmaceuticals held 88.40%of Baiyunshan. All three companies are controlled by Baiyun Mountain.

The specific cash out operation method is that the drug manufacturer signed a cooperation agreement with the drug agent to add the designated "dealer" in the procurement session of the raw and drug. Double -fold sales to drug manufacturers. Pharmaceutical manufacturers further transmit the virtual high price of raw drugs to the price of factory and bidding network prices in the name of "raising price increases and high production costs". The "dealer" of the raw medicine "dealer" is actually controlled by the drug agent, and the difference in income obtained by the low -selling and high -sale and high -sale raw medicines is cash to the drug agent for medical business bribery.

Taking cephalosporin sulfur sulfur as an example, Baiyunshan Pharmaceutical (Preparation Factory) and Baiyunshan Chemical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmaceutical Pharmacea Instead, the cash -up process is set up, and the "dealer" controlled by the agent controlled by the agent will be transferred to the preparation factory at low buying high. The preparation factory uses the high price of cephalosporin sulfurizer in the cost of the raw medicine drug, which makes the drug production and circulation link on the surface and other policies and regulations to avoid supervision.

The National Medical Insurance Bureau reported that at present, three enterprises including Tianxin Pharmaceuticals have rectified 87 kinds of drugs such as cephalosporin sulfurizes across the country as required, and eliminating the current prices for the implementation of bribes such as bribery. The decline is more than 50%, and some product regulations have been stopped purchased.

Guangdong Province ordered three companies including Tianxin Pharmaceutical and other related companies to comprehensively rectify marketing models to stop relevant illegal operations. In addition, relevant departments are investigating and punishing in accordance with the law for those suspected of disciplinary, illegal, and crimes.

On August 10, Guangzhou Baiyunshan Pharmaceutical Group issued a explanation of this release: attaches great importance to this report, and has taken a series of rectification measures. The three companies involved have stopped cooperation with relevant agents and dealers, comprehensively rectified the marketing model, and carried out prices or withdrawn from related products nationwide. Three companies related responsible persons have been dismissed or suspended.

Earlier has been canceled by many provinces

Before Bai Yunshan was notified by the State Medical Insurance Bureau, it was canceled by many provinces. Among them, the reason why Anhui Pharmaceutical Concentrated Purchasing Purchasing Platform was "according to the requirements of the National Medical Insurance Bureau", and the Shandong Public Resources Trading Center stated that its "drug discontinued or duplicate products". Bai Yunshan has also proactively applied for the revocation of drugs. The reasons include the unable to produce, the product delisting, etc. The reporter noticed that the National Medical Insurance Bureau reported that the prices of raw and drugs involved in involved were notified. Bai Yunshan had previously applied to the Heilongjiang Provincial Medical Insurance Bureau for revocation of the hanging network on the grounds of a high cost price price.

Specifically, on June 23, 2022, the Ningxia Hui Autonomous Region Public Resources Trading Network issued a notice of termination of the drug hanging network that the acetamin phenol -mixed suspension of the hexin Pharmaceutical was terminated. The Anhui Pharmaceutical Concentrated Purchasing Platform has also issued two related announcements, and the wording is relatively tough. On June 10, 2022, its announcement stated that according to the requirements of the National Medical Insurance Bureau, the relevant drugs produced by Baiyunshan Pharmaceuticals, Tianxin Pharmaceutical and Jingxiu Pharmaceuticals were removed and priced. Supply and meet the needs of clinical medication. Since then, Tianxin Pharmaceutical has complained about the rectification of some drug prices involving the company. According to the relevant standards of the National Medical Insurance Bureau's price rectification, the selection of drugs in the national collection of drugs uniformly rectified the price of "appraisal products" approved by the State Medical Insurance Bureau. Drugs that do not accept the price of this rectification, uniformly withdraw the network. At the same time, it is emphasized that the enterprise does not accept the application of a pharmaceutical withdrawal from the company on the grounds of "unable to supply".

The Shandong Provincial Public Resources Trading Center issued the "Notice on Supplemental Public Notice on Part of the Products" on June 8, 2022, saying that drug discontinuation refers to the production enterprise that has stopped the production of the product and currently none of the provincial -level drug centralized procurement platforms none of them none of them. Hanging network products. Repeated products refer to the products that are repeatedly declared, and the products after the consistency of the quality and efficacy can be revoked before the repetitive products before the evaluation.

On April 19, 2022, the Guangzhou Public Resources Trading Center issued a notification that drugs that could not be produced normally, product delisting and other factors were suspended according to enterprise applications, including Tianxin Pharmaceutical. On June 10, the Guizhou Public Resources Trading Center issued a notice that according to the Baiyunshan Pharmaceutical General Plant and Tianxin Pharmaceutical, the price reduction or withdrawal of related drugs.

On June 14, 2022, the Shanxi Provincial Pharmaceutical Real Estate Bidding and Procurement Center issued an announcement. According to the enterprise application, 3 companies including Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical Factory applied for to cancel 89 pharmaceutical product regulations on the platform hanging on the platform. qualifications. At the same time, the three companies did not accept the product within two years after the suspension of the network. New Yellow River reporters noticed that the three companies that withdrew from Shanxi Province were involved in the company.

According to the "Notice on the withdrawal of some drugs from the provincial procurement platform" issued by the Heilongjiang Provincial Medical Insurance Bureau in August 2021, a total of 4 drugs in Baiyunshan Zhongzhong Pharmaceutical and Baiyunshan Mingxing Pharmaceuticals exited the provincial procurement platform, because the cost of raw materials and other aspects Increased, the price of winning bids was lower than the cost price, and it was unable to continue to ensure normal supply.

Future product sales will be "affected"

A reporter from Xinhuanghe found that in many places, it has notified the company's dishonesty.

In August 2021, the Hunan Provincial Public Resources Service Platform issued the "Notice on the results of Hunan Provincial Pharmaceutical Price and Recruitment of Credit Credit Levels", which rated Tianxin Pharmaceuticals into "general". In March 2022, the Gansu Provincial Medical Insurance Bureau issued the "Results of the Processing of Credit Behavior of Enterprises in Gansu Provincial Procurement Drugs". Tianxin Pharmaceuticals did not set up regional procurement agreements to withdraw, involving agreed procurement to reduce the amount. Production enterprises have a bad record once.

After Bai Yunshan's pharmaceutical companies were notified this time, the outside world speculated that its degree of damage was speculated. In this regard, Bai Yunshan issued an announcement saying that in 2021, the three companies involved involved in the withdrawal of the network products were RMB 1.15 million, and the gross profit reduction of prices was RMB 320 million, accounting for the company in 2021, the proportion of the gross profit of the audit of the company in 2021, respectively, respectively. It is 0.12%and 2.45%. From January to March 2022, the three companies involved the gross profit of the withdrawal of the net products was RMB 1.12 million, and the gross profit reduction of prices was 102 million yuan. It is 0.25%and 2.13%.

From this point of view, the proportion of products involved in the company's business income is not high. Bai Yunshan also said that the incident will have a certain impact on the company's future product sales, but it will not have a significant impact on product operating performance.

According to reports, industry insiders pointed out that the public notification of Baiyun Mountain's drug prices proved the determination to crack down on the regulations of the pharmaceutical industry at the national level. The National Medical Insurance Bureau stated that it will continue to guide the provinces with relevant departments to do a good job of medical prices and recruitment of credit evaluation in accordance with the implementation of corporate rectification and the facts identified by the relevant departments, and cooperate with relevant departments to continue to correct the incorrect field of pharmaceutical purchase and sales. wind.

Edit: Weekend

- END -